Study Protocol: Study on Incidence and Risk Factors of Mold Infections in Children During Leukemia Treatment

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

800 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-04-01

Study Completion Date

2025-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study aims to evaluate the occurrence, mortality, and risk factors for invasive mold infections (IMI) in children treated with chemotherapy for acute leukemia in Denmark. The study will be a retrospective nationwide survey study of all children who received first-line chemotherapy for acute leukemia from 2008 to 2022 in Danish pediatric oncology units. The study population will include approximately 800 children under the age of 18. Data will be collected from medical records, hospital databases, and national databases. When the IMI subgroup has been identified, this will be compared to the leukemic group that did not develop IMI. Statistical analysis can then determine the occurrence, mortality rate, and possible IMI risk factors.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Prediction Model of Hematological Recovery After High-dose Chemotherapy in Pediatric Solid Tumor

NCT05024331

Pediatric Solid Tumor

COMPLETED

Role of Children in Transmission of COVID-19 to Immunocompromised Patients

NCT04407546

Immunosuppression

TERMINATED

Nebulized Amphotericin B Lipid Complex in Invasive Pulmonary Aspergillosis in Paediatric Patients With Acute Leukaemia

NCT01615809

Invasive Pulmonary Aspergillosis Lymphoblastic Leukaemia Myeloblastic Leukaemia +2 more

COMPLETED PHASE2

Cardiometabolic Status in Childhood Acute Lymphoblastic Leukemia

NCT01688752

Acute Lymphoblastic Leukemia

WITHDRAWN

Treatment of Newly Diagnosed High Risk Pediatric Acute Lymphoblastic Leukemia

NCT06184009

Pediatric Acute Lymphoblastic Leukemia

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Chemotherapy can weaken children's immune system, making them vulnerable to infections, including invasive mold infections (IMI), caused mainly by Aspergillus spp. The at-risk population for IMI in children with acquired immunodeficiency is patients with prolonged granulocytopenia due to hematologic malignancies treated with chemotherapy or allogeneic hematopoietic stem cell transplantation (HSCT) recipients and children receiving long-term corticosteroid treatment. Incidences and mortality rates are often reported as high.

In a retrospective cohort study, we aim to obtain an epidemiological overview of IMI in children receiving first-line treatment for acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL) in Denmark from 2008 to 2022 and identify possible risk factors, including treatment-related adverse effects.

Objectives

1. To determine and compare the incidence of IMI in childhood AML and ALL during first-line chemotherapy in Denmark.
2. To determine and compare the mortality of IMI in childhood AML and ALL during first-line chemotherapy in Denmark.
3. To explore risk factors for IMI in childhood AML and ALL during first-line chemotherapy in Denmark.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Leukemia, Myeloid, Acute Acute Lymphoblastic Leukemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \<18 years at the time of inclusion
* Received first-line treatment for ALL or AML
* Treatment at a Danish tertiary pediatric oncology unit (Rigshospitalet, Aarhus University Hospital, Odense University Hospital, and Aalborg University Hospital)
* Treatment initiation January 1st, 2008, to December 31st, 2022

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No